Literature DB >> 11899153

Risk of second primary malignancies in patients with cutaneous melanoma.

M H Schmid-Wendtner1, J Baumert, C M Wendtner, G Plewig, M Volkenandt.   

Abstract

BACKGROUND: In several studies an increased risk for development of breast cancer, malignant lymphoma and neoplasms of the kidney as second primary cancers in patients with cutaneous melanomas was discussed.
OBJECTIVES: To determine the risk for development of second primary neoplasms in patients with cutaneous melanomas.
METHODS: A prospective study was performed between 1977 and 1992 to evaluate the occurrence of second primary malignancies in 4597 patients (2083 men, 2514 women) with invasive cutaneous melanomas, diagnosed and treated at the Department of Dermatology and Allergology, Ludwig-Maximilians-University, Munich, Germany.
RESULTS: During a median follow-up of 7.2 years, 296 of 4597 patients (6.4%) developed one or more neoplasms at the time of or subsequent to the diagnosis of the first cutaneous melanoma. More than half of these patients developed one or more further melanomas (152, 3.3%). Cancers of the breast, prostate, colon, rectum and kidney occurred less frequently. Statistical calculations revealed a 33.8-fold increased risk for the development of a second melanoma in the entire group [relative risk 38.5 for men (95% CI, 30.4-48.1), 29.0 for women (95% CI, 22.0-37.5)]. Moreover, a significantly increased risk for the development of kidney carcinoma in men was found [relative risk 3.5 (95%, CI, 1.4-7.2)].
CONCLUSIONS: Thorough follow-up and skin examination in patients with cutaneous melanomas is recommended for early detection of other primary melanomas. Furthermore, ultrasound examinations routinely performed in melanoma patients for the detection of melanoma metastases may also be of value for early detection of kidney carcinomas in male patients.

Entities:  

Mesh:

Year:  2001        PMID: 11899153     DOI: 10.1046/j.1365-2133.2001.04507.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  15 in total

1.  Increased risk of second primary cancers after a diagnosis of melanoma.

Authors:  Porcia T Bradford; D Michal Freedman; Alisa M Goldstein; Margaret A Tucker
Journal:  Arch Dermatol       Date:  2010-03

2.  Initial response of renal cell carcinoma to vemurafenib in a patient treated for metastatic melanoma.

Authors:  Gregory W Hosier; Matthew T Roberts
Journal:  Can Urol Assoc J       Date:  2016-09-13       Impact factor: 1.862

Review 3.  Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Authors:  Balazs I Bodai; Phillip Tuso
Journal:  Perm J       Date:  2015

4.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

5.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31

6.  Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma.

Authors:  A W L Bayci; D A Baker; A E Somerset; O Turkoglu; Z Hothem; R E Callahan; R Mandal; B Han; T Bjorndahl; D Wishart; R Bahado-Singh; S F Graham; R Keidan
Journal:  Metabolomics       Date:  2018-08-03       Impact factor: 4.290

7.  Risk of subsequent primary tumor development in melanoma patients.

Authors:  Veronika Tóth; Zsófia Hatvani; Beáta Somlai; Judit Hársing; János F László; Sarolta Kárpáti
Journal:  Pathol Oncol Res       Date:  2013-05-17       Impact factor: 3.201

Review 8.  Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review.

Authors:  Kate D Cromwell; Merrick I Ross; Yan Xing; Jeffrey E Gershenwald; Richard E Royal; Anthony Lucci; Jeffrey E Lee; Janice N Cormier
Journal:  Melanoma Res       Date:  2012-10       Impact factor: 3.599

9.  Appearance of malignant melanoma after a non-cutaneous cancer diagnosis.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Cecilia Luci; Paola Corsetti; Stefano Calvieri
Journal:  Ecancermedicalscience       Date:  2013-05-07

10.  Modification of second cancer risk after malignant melanoma by parental history of cancer.

Authors:  H Zhang; J Lorenzo Bermejo; J Sundquist; K Hemminki
Journal:  Br J Cancer       Date:  2008-07-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.